SLC5A2 and chronic kidney disease: However, a 2023 multicenter observational prospective cohort study [60] is going to evaluate the effect of the SGLT2 dapagliflozin in patients with both Fabry disease and CKD at stages I–III, a genetic and biochemical diagnosis of Fabry disease and albuminuria for at least 6 months despite treatment with a stable dose of ERT or Migalastat for 12 months, and ACEi or ARB titrated to the maximum tolerated dosage for at least 6 months.